|Podcasts|February 18, 2021
Episode 76: Repatriating Pharma
Author(s)Elaine Quilici
Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.
Advertisement
Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, discusses the drive to bring pharma manufacturing back to a company’s home country and the issues involved in doing so.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5